My main research interests include the study of cytokines and other molecular pathways regulating inflammation, innate and adaptive immunity, particularly the function of T lymphocytes, as well as the interplay between immune cells and cells that comprise the tissue architecture, namely epithelial cells, fibroblasts and other mesenchymal cell types, with the goal of dissecting how this interplay shapes effector responses in the disease target organ, potentially leading to fibrosis.

These interests are reflected in my work on the TNF superfamily of cytokines, particularly the elucidation of novel biology and the discovery of therapeutic approaches to targeting the CD40L/CD40 and the TNF-like weak inducer of apoptosis (TWEAK)/Fn14 pathways and their advancement into clinical development.

I have cultivated more than 20 years of experience in drug discovery research and development in the biopharmaceutical industry, contributing to drug target identification, mechanistic and translational studies, and the advancement of promising therapeutic candidates into clinical development for the treatment of autoimmune and inflammatory diseases.

My research goals are to continue to explore and identify new molecular mechanisms underlying the pathophysiology of autoimmune, inflammatory and fibrotic diseases, and thereby devise novel approaches to therapeutic targeting.


  • Postdoctoral Fellow, Laboratory of Dr. Richard Flavell, Biogen, Inc., Cambridge, MA, 1985–1988
  • Ph.D., Laboratory of Dr. Henry Wortis, Tufts University Sackler School of Biomedical Science, Boston, MA, 1985

Selected Publications

See more scientists